New Discovery Could Lead to New Treatments for Anemia in Juvenile Idiopathic Arthritis, Lupus, and Malaria

Juvenile idiopathic arthritis, Lupus, and Malaria are diseases which currently have limited treatment options. But a new discovery by researchers at the Benaroya Research Institute (BRI) could potentially lead to…

Continue Reading New Discovery Could Lead to New Treatments for Anemia in Juvenile Idiopathic Arthritis, Lupus, and Malaria
New Combination Therapy for Renal Cell Carcinoma Gains European Approval
source: pixabay.com

New Combination Therapy for Renal Cell Carcinoma Gains European Approval

According to a story from BioPortfolio, the Bristol-Myers Squibb Company recently announced that the European Commission has recently approved the first combination treatment for renal cell carcinoma available in the…

Continue Reading New Combination Therapy for Renal Cell Carcinoma Gains European Approval
ICYMI: FDA Clears New Drug Application and Grants Priority Review for Potential Ehlers-Danlos Syndrome Drug
frolicsomepl / Pixabay

ICYMI: FDA Clears New Drug Application and Grants Priority Review for Potential Ehlers-Danlos Syndrome Drug

According to a story from BioPortfolio, the pharmaceutical company Acer Therapeutics, Inc., recently announced the company's New Drug Application (NDA) has been accepted by the US Food and Drug Administration…

Continue Reading ICYMI: FDA Clears New Drug Application and Grants Priority Review for Potential Ehlers-Danlos Syndrome Drug

Rising Cost of Drug Development isn’t Slowing Down Researchers Working to Uncover Novel Therapies for Rare Diseases

Every day the scientific community makes progress in the study of rare disease. Research in the field has advanced exponentially in recent years and we're starting to see more treatments…

Continue Reading Rising Cost of Drug Development isn’t Slowing Down Researchers Working to Uncover Novel Therapies for Rare Diseases

Editor’s Choice: CIDP Athletes, Parents Turned Researchers, and Commonplace Medicines with Concerning Correlations

Happy Thursday! We hope everyone's new year is off to a good start. If you're in need of some inspiration, we're highlighting a story of a woman with CIDP accomplishing…

Continue Reading Editor’s Choice: CIDP Athletes, Parents Turned Researchers, and Commonplace Medicines with Concerning Correlations

Stanford PhD Candidate Creates Platform for Parkinson’s Disease Patients to Share Their Story with Researchers

"Beyond research motivation, I want to give a voice to the disease to help researchers empathize and further understand who all their hard work is going toward." These are words from…

Continue Reading Stanford PhD Candidate Creates Platform for Parkinson’s Disease Patients to Share Their Story with Researchers
Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial
source: pixabay.com

Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Prader-Willi Syndrome (PWS) is caused by deleted genes on chromosome 15. This results in improper signaling of satiety, leading to obesity. Individuals with the condition can suffer from respiratory/cardiac disease, gastric…

Continue Reading Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Myasthenia Gravis (MG) is a progressive autoimmune disorder which results in the weakening of muscles. Most people with the condition are able to manage their symptoms with treatment and have…

Continue Reading Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation

Limb Girdle Muscular Dystrophy Type 2D (LGMD2D), also called alpha-sarcoglycanopathy, is a form of muscular dystrophy which is caused by a defected SGCA gene. It causes the body to lose function of…

Continue Reading Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation
Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients